Drugs / EDP167
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07412080 | Jul → Dec 2025 | — | Eddingpharm (Zhuhai) Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07489209 | Feb → Oct 2026 expected | homozygous familial hypercholesterolemia | Eddingpharm (Zhuhai) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | Eddingpharm (Zhuhai) Co., Ltd. | Results 亿腾嘉和多款产品研究成果即将公布 创新研发实力再上台阶 eddingpharm.com ↗
EDP167的FIH研究显示整体安全性和耐受性良好，初步展现了全面改善致动脉粥样硬化血脂谱的能力，提示EDP167有潜力成为新一代的降脂药物。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-08-21 | Eddingpharm (Zhuhai) Co., Ltd. | 亿腾嘉和多款产品研究成果即将公布 创新研发实力再上台阶 eddingpharm.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP167 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07412080 ↗ |
| Action | Inhibit | “EDP167 is a novel GalNAc-conjugated siRNA therapeutic that selectively silences hepatic ANGPTL3 mRNA expression” NCT07412080 ↗ |
| Modality | Small interfering RNA (siRNA) | “EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3” NCT07412080 ↗ |
| Route | Subcutaneous | “following a single subcutaneous injection of EDP167” NCT07412080 ↗ |
| Target | ANGPTL3 | “EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3” NCT07412080 ↗ |